ArticleFrontiers in pharmacology2025
Preclinical evaluation of uPAR-ICG-FVIOs for dual-mode imaging and magnetic hyperthermia therapy in pancreatic cancer.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular Imaging in Pancreatic Cancer: Current Applications and Future Perspectives.Pharmaceuticals (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study presents a novel targeted nanomedicine for pancreatic cancer imaging and local magnetic hyperthermia therapy (MHT): urokinase plasminogen activator receptor (uPAR)-targeted, indocyanine green (ICG)-conjugated ferrimagnetic vortex iron oxide (FVIOs) nanorings (u-I-FVIOs). uPAR is a cancer-selective membrane protein, ICG is a clinically approved near-infrared (NIR) dye, and FVIOs are well-characterized nanorings with high efficiency in heat conversion under alternating magnetic field (AMF). Methods & Results: We systematically evaluated the physicochemical and biological properties of u-I-FVIOs and demonstrated their tumor targeting capacity and AMF-dependent cancer cytotoxicity. Following intravenous (I.V.) administration, u-I-FVIOs produced robust fluorescence and MRI signals in tumors, achieving a tumor-to-background ratio of 3.5-4.5 at 12-24 h post-injection, compared with 2.5-3.0 for I-FVIOs and 1.5-2.5 for the ICG group. In a PANC-1 subcutaneous pancreatic tumor mouse model, animals received one of four treatments: Blank, Blank + AMF, u-I-FVIOs, or u-I-FVIOs + AMF. The Blank and u-I-FVIOs were administered intratumorally (I.T.), AMF exposure was applied for 600 s after the I.T. injections. u-I-FVIOs + AMF resulted in near-complete tumor regression (tumor suppression rate: 93%; mixed-effects model: Conclusion: This study presents the first theranostic applications of u-I-FVIOs, highlighting their potential as a dual-mode imaging and targeted MHT agent for pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.